Methods of treating proliferative diseases
Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
1. A method of treating a proliferative disease in a patient, which comprises administering to the mammal having or suspected to have the proliferative disease, a therapeutically effective amount of the compound of Formula I:
or a pharmaceutically acceptable salt or solvate thereof, wherein the therapeutically effective amount is from about 12 mg to about 200 mg per day, and wherein the compound is administered on an empty stomach.
2. The method of claim 1 , wherein the compound is administered at least about 2 hours after meal.
3. The method of claim 1 , where in the disease is acute myeloid leukemia.
4. The method of claim 1 , where in the disease is relapsed or refractory acute myeloid leukemia.
5. The method of claim 1 , wherein the patient is 60 years or older and relapsed after a first line cancer therapy.
6. The method claim 1 , wherein the patient is 18 years or older and is relapsed after a second line cancer therapy.
7. The method of claim 1 , wherein the patient has prior myelodysplastic syndrome, unfavorable cytogenetics at diagnosis, or ECOG performance status of 2.
8. The method of claim 1 , wherein the proliferative disease is acute myeloid leukemia.
9. The method of claim 1 , wherein the disease is relapsed or refractory.
10. The method of claim 1 , further comprising administering a therapeutically effective amount of a second therapeutic agent.
11. The method of claim 10 , wherein the second therapeutic agent is an anticancer agent.
12. The method of claim 1 , further comprising a diagnostic step for determining the presence of a constitutively activating FLT3 mutant.
13. The method of claim 1 , wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof is administered orally.
14. The method of claim 1 , wherein the compound of formula I, or a pharmaceutically acceptable salt, or solvate thereof, is administered once per day for twenty eight days.
15. The method of claim 9 , wherein the mammal with the refractory leukemia has a constitutively activating FLT3 mutation.
16. The method of claim 3 , wherein the mammal with leukemia has a FLT3 missense mutation.
17. The method of claim 3 , wherein the mammal with acute myeloid leukemia has a FLT3 internal tandem duplication mutation.
18. The method of claim 3 , wherein the mammal with acute myeloid leukemia has a FLT3 point mutation.
19. The method of claim 1 , wherein the proliferative disease is a bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, gastrointestinal stromal tumor, melanoma, mast cell tumor, neuroblastoma, or germ cell tumor hematologic malignancy.
20. The method of claim 1 , wherein the amount is about 200 mg per day.
21. The method of claim 1 , wherein the amount is about 150 mg per day.
22. The method of claim 1 , wherein the amount is about 135 mg per day.
23. The method of claim 1 , wherein the amount is about 100 mg per day.